| STATUS | VLA-4 ANTAGONISTS (Pre-Clinical) With a complex biological process such as the one that triggers asthma, there is often more than one way to attack the problem. A case in point is our collaboration with Schering Plough Corporation to discover and optimize VLA-4 antagonist compounds to treat asthma. In June 2002, Schering chose to take one of our VLA-4 antagonists into the final stages of testing prior to beginning clinical development. Unlike other VLA-4 antagonists that are in development, our candidate is a small molecule compound and is therefore orally available. We believe our VLA-4 compound may block the action of certain cell adhesion molecules and thereby prevent inflammation in a highly specific manner |
| UPDATE | 06.02 |
| COMPANY |
- Encysive Pharma. - Schering Plough |
|
Want more information ? Interested in the hidden information ? Click here and do your request. |